SCHEMBL8337250

SCHEMBL8337250

CCNC(=O)CN(c1ccccc1OC)S(=O)(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.58
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
TP53 P04637 2/20 0.55
ESR1 P03372 1/20 0.53
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
HTT P42858 1/20 0.52
ATM Q13315 1/20 0.52
GAA P10253 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1040894 0.83 HCRTR2 (0.62) MEN1KMT2AESR1KEAP1NFE2L2
SCHEMBL8337800 0.81 PTGER1 (0.62) PTGER1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1039017 0.79 TEAD1 (0.55) MAPTSMN1; SMN2MEN1KMT2ATP53
SCHEMBL1038651 0.76 L3MBTL1 (0.47) MAPTSMN1; SMN2MEN1KMT2ATP53
SCHEMBL16557468 0.75 HPGD (0.81) MAPTSMN1; SMN2TP53ALDH1A1HPGD
SCHEMBL8337641 0.74 HPGD (0.55) PTGER1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL18101489 0.73 SMN1; SMN2 (0.70) MAPTSMN1; SMN2TP53ALDH1A1HPGD
SCHEMBL12956486 0.73 HSD17B10 (0.46) PTGER1SMN1; SMN2MEN1KMT2ATP53
SCHEMBL8338556 0.73 PTGER1 (0.55) PTGER1MAPTSMN1; SMN2KEAP1NFE2L2
SCHEMBL2174816 0.72 SMN1; SMN2 (0.57) PTGER1MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004033418-A2 SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2004-04-22 WO disclosed